Bayesian Network Meta-Analysis of Targeted Therapies for Advanced Thyroid Cancer

9 randomized controlled trials involving 1,760 patients with radioiodine-refractory differentiated thyroid cancer were analyzed. The data, compiled by Pin Wang and last updated in March 2026, includes hazard ratios and odds ratios for progression-free survival, overall survival, objective response rate, and adverse events. Results are presented in an Excel file.

Use Cases

• Compare the efficacy of targeted therapies like lenvatinib and apatinib based on progression-free survival hazard ratios.
• Rank treatments for safety based on the reported surface under the cumulative ranking curve (SUCRA) values for adverse events.
• Analyze time-dependent efficacy patterns of tyrosine kinase inhibitors based on the described waning benefit of apatinib beyond 6-9 months.
• Validate Bayesian network meta-analysis methods using the provided hazard ratios and credible intervals for multiple endpoints.

Strengths

• Includes data from 9 randomized controlled trials, a standard for high-quality clinical evidence.
• Analyzes 1,760 patient records across multiple endpoints (PFS, OS, ORR, AEs).
• Uses Bayesian network meta-analysis, a sophisticated statistical method for indirect treatment comparisons.
• Provides specific ranking metrics like SUCRA values for each treatment and outcome.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for certain analyses.
• The dataset is very small (34.5 KB), indicating it contains summary-level results rather than patient-level data.

Provenance

Source

figshare, author Pin Wang

Collection Method

Systematic review and Bayesian network meta-analysis of six electronic databases.

Freshness

Last updated 2026-03-18 07:35:11